Where Will Quantum Computing Stock Be in 1 Year?

Quantum Computing Inc. (QUBT/QCI) has begun shipping photonic quantum chips from its first foundry opened in May but generated only $484,000 in revenue in the first nine months of 2025 and is expected to record $777,000 revenue and a net loss near $24 million for the full year. With a $2.7 billion market capitalization, the stock trades at an outsized 3,481x this year’s sales versus 159x for IonQ and 1,134x for Rigetti; management does not expect mass production until a second fab within ~three years, and analysts project revenue rising to $2.1 million in 2026 with losses widening to $40.5 million, leaving significant execution, cash‑raise and competition risks.

Analysis

Market structure: Photonic incumbents (QUBT, Xanadu, PsiQuantum suppliers, optical foundries) stand to gain long-term if photonics proves cheaper at scale, while superconducting (IBM, RGTI) and trapped-ion (IONQ) players face competitive pressure on cost-per-qubit assumptions. Today supply is scarce and concentrated — QUBT shipped nominal chips ($484k rev YTD; market cap ~$2.7B) so pricing power is likely to be buyer-driven for 12–36 months until second fab comes online. Equity issuance risk will increase supply of QUBT shares and compress returns; broader tech sentiment may reprice small-cap quantum names together.

Risk assessment: Tail risks include tech failure to reduce error rates (high-impact), inability to mass-produce or a failed fab build (financial/capacity shock), or a large dilution event (>10–20% equity raise within 12 months). Time horizons: days – elevated IV and headline-driven swings; months – cash-raising and pilot contract milestones; years – second fab and true mass production (>3 years). Hidden dependencies: reliance on conventional CMOS foundries, optical-component suppliers, and government contracts; losing one partner could derail timelines quickly.

Trade implications: Favor defined-risk bearish exposure to QUBT and relative long exposure to proven incumbents (IONQ) or diversified suppliers (large-cap IBM, NVDA indirectly via optics accelerate downstream compute demand). Use 3–12 month option structures to reflect near-term dilution and milestone windows (see concrete trades below). Reduce outright long exposure to pure-play small photonics names until QUBT demonstrates >5x revenue growth YoY or secures >$50M multi-year contracts.

Contrarian angles: Consensus undervalues the binary outcome — either photonics solves scale/cost (major re-rating) or it stalls and QUBT collapses; current pricing (3,481x 2025 sales) implies near-certain success and is asymmetric. Historical parallel: SPAC-era pre-revenue tech names that re-rated sharply on a single failed milestone. Unintended consequence: heavy shorting could be squeezed if QUBT lands a large government foundry contract, so size and use of spreads are critical.

Key Decisions for Investors

• Establish a defined-risk bearish position on QUBT sized 1.0–1.5% of portfolio via a 6-month put spread: buy 6-month $10 puts and sell 6-month $5 puts (or nearest available strikes) to cap max loss; exit/roll if QUBT announces a funded second-fab start within 12 months or posts cash runway >24 months.
• Enter a pair trade: long IONQ 2–3% notional vs short QUBT 1.5% notional to play relative fundamentals; target 30–50% relative return, trim if IONQ outperforms QUBT by +50% or if IONQ falls >25% absolute.
• Buy IONQ 9–12 month call spread (e.g., 12-month 30% OTM/50% OTM) sized 1–2% to capture re-rating on commercial traction; fund with sale of QUBT 3–6 month OTM calls (covered by the put spread above) to monetize elevated IV.
• Reduce exposure to small-cap photonics and pure-play quantum ETFs by 50% within 30 days unless names report sequential monthly revenue growth >20% or secure >$25M multi-year contracts; re-open sizing only after demonstrable cash/runway extension (>12 months) or mass-production milestone confirmation.